0000899243-22-027635.txt : 20220803 0000899243-22-027635.hdr.sgml : 20220803 20220803180104 ACCESSION NUMBER: 0000899243-22-027635 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220801 FILED AS OF DATE: 20220803 DATE AS OF CHANGE: 20220803 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON DAVID LEE CENTRAL INDEX KEY: 0001733883 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 221133984 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS STREET 2: 171 OYSTER POINT BLVD, STE. 300 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001733883 JOHNSON DAVID LEE C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Commercial Officer Common Stock 2022-08-01 4 M 0 6770 A 55493 D Common Stock 2022-08-01 4 F 0 2342 32.40 D 53151 D Restricted Stock Units 2022-08-01 4 M 0 3125 0.00 D Common Stock 3125 3125 D Restricted Stock Units 2022-08-01 4 M 0 3645 0.00 D Common Stock 3645 10935 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Includes 299 shares of Common Stock acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,770 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. /s/ Miguel Carrillo, Attorney-in-Fact 2022-08-03